AIM-quoted near-patient molecular diagnostics company Genedrive has appointed Tom Lindsay as a non-executive director, effective immediately.
Lindsay, a 35 year veteran of the diagnostics sector, who had most recently worked for Alere, where he held roles such as president of Africa, president of commercial operations for Africa, and business development director for Africa before retiring in 2017, led the introduction and successful commercialisation of a number of key HIV screening and HIV patient management point of care diagnostics technologies throughout the continent.

Prior to joining Alere, Lindsay held senior commercial roles at Trinity Biotech including marketing and sales director and business development director for Africa, Middle East and India.

Ian Gilham, non-executive chairman of Genedrive, said, "Tom has exceptionally strong experience in commercialising diagnostics in Africa and other low and middle-income markets. We look forward to working with him as we continue to deliver on the opportunities presented by our Genedrive HCV ID test, which is the first decentralised test to market, and by the Genedrive platform more widely."

Of his appointment, Lindsay added, "The simplicity, low-cost, speed and versatility of the Genedrive platform represent significant strengths for decentralised molecular diagnostics. I am excited to join the board and about the prospects for Genedrive across multiple indications and markets."

As of 1040 BST, shares had dropped 3.90% to 37.00p.

Related share prices
Genedrive (GDR) share price